Recently, GSK developed a type II/III RIPK1 inhibitor (GSK2982772) that is currently in clinical trial phase IIa for the treatment of psoriasis, rheumatoid arthritis and ulcerative colitis59,60. This evidence concerns the gene RIPK1 and psoriasis.